AZD5492
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AZD5492, covering 2026-03-17 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. [Phase 1, Phase 2]